Dr. Andrea Giuseppe Mesén Fainardi
Médico Psiquiatra

Professor of Psychiatry, University of Costa Rica.
Director of the Costa Rican Medical Research Center.
Co-Investigator of the following Research Trials:

NKF100096:A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressive Disorder. GSK. Active

NAA104606:
A Multi Centre, Double-Blind, Double-Dummy, Placebo- Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia. GSK. Active

D1447C00134: 
An International, Multi-centre, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel TM , single oral 300 mg or 600 mg dose) and Paroxetine as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks. Astra Zeneca. Active
 
R076477-BIM-3004:
A randomized, double-blind, active and placebo controlled, parallel group, multicenter study to evaluate the efficacy and safety of extended-release paliperidone as maintenance treatment after an acute manic or mixed episode associated with Bipolar I Disorder. Active

A1281134:
Six week, double-blind, placebo controlled phase III Trial evaluating the efficacy, safety and Pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia. Active

SND103288: A ten week multicentre, randomized, double-blind, placebo and active-controlled, parallel-group, flexible-dose study evaluating the efficacy, safety and tolerability of GSK372475 or paroxetine compared to placebo in adult subjects diagnosed with major depressive disorder. Active

Co-investigator of the research project  Detection of the major loci involved in the etiology of schizophrenia, State University of Nueva York, University of California at Irvine, University of California at San Francisco, Nathan Kline Institute and Pritzker Foundation. Principal Investigators: Lynn DeLisi, William Byerley.

Co-investigator Research Project University of Pennsylvania Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine, Principal Investigator Dr. Steven J Siegel.

Professor of Psychiatry at University of Costa Rica

Co-director of TMS clinics Costa Rica

Member of the Costa Rican Psychiatric Association.

Founder member of the Costa Rican Collage of NuroPsychopharmacology.

Founder Member of the World Association of Young Psychiatrists and Trainees.

Former coordinator of the Research area of the mental Health Department of the Costa Rican Social Security.

Former member of the Psychotropic Drugs Vigilante Board of the Minestry of Health.

Fellow for the Xth World Congress of Psychiatry, WPA, Yokohama, Japan 2002

Fellowship on Transcranial Magnetic Stimulation at The Mind Care Center, Vancouver, Canada.

Fellowship on Transcranial Magnetic Stimulation at Harvard Medical School, Boston Massachusetts.

Awarded with 2 Young Investigators Awards from The National Alliance for the Research of Schizophrenia and Depression (NARSAD)  2000 and 2003.

PUBLICATIONS

1.    Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lonnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoega T, Helgason T. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet. 2003 Jul;73(1):34-48.
 

2.    DeLisi LE, Mesen A, Rodriguez C, Bertheau A, LaPrade B, Llach M, Riondet S, Razi K, Relja M, Byerley W, Sherrington R. Genome-wide scan for linkage to schizophrenia in a Spanish-origin cohort from Costa Rica. Am J Med Genet. 2002 Jul 8;114(5):497-508.

3.    DeLisi LE, Mesen A, Rodriguez C, Bertheau A, LaPrade B, Llach M, Riondet S, Razi K. Clinical characteristics of schizophrenia in multiply affected Spanish origin families from Costa Rica. Psychiatr Genet. 2001 Sep;11(3):145-52.

4.    Cooper K, Mesén A, Galke B, Llach M, Laprade B, Rodríguez C, Riondet S, Bertheau A, Byerley W. Suggestive linkage of schizophrenia to 5p13 in Costa Rica. Molecular Psychiatry. On Press

ABSTRACTS

1.    Mesén A., Rodríguez C., Bertheau A., et al.  “Isolated Founder Population in Costa Rica for Genetics Studies of Schizophrenia”:  abstract for the VIII  World Congress in Genetic Psychiatry, Versailles, France. October 2000.

2.    Mesén A., Rodríguez C., Bertheau A., et al.  “A Genome Scan of a Large Costa Rican Family Affected by Schizophrenia” : abstract for the  XIth World Congress of Psychiatric genetics, Quebec, Canada October 2003

TALKS

1.    Mesén A.   “A genome-wide scan for linkage to schizophrenia in a Spanish-origin cohort from Costa Rica: the genetic isolate paradigm in perspective”. Charla para el X Congreso Mundial de Psiquiatría Genética, Bruselas, Bélgica Octubre 2002.

2.    Mesén A. “Investigación Psiquiátrica en  Costa Rica” Charla para el XIX Congreso Naciona de Psiquiatría de Venezuela, Maracaibo, Vnezuela, Octubre 2004.

3.    Mesén A.  “Investigación en Costa Rica desde la perspectiva del investigador”  Charla para el II Congreso de Psicología de la Universidad Fidelitas, San José, Costa Rica, Septiembre 2004

4.    Mesén A “La perspectiva Cognitiva en la Esquizofrenia” Charla de apertura para el XX Congreso centroamericano de Psiquiatría, Ciudad de Panamá Marzo 2006

5.    Mesén A “Estimulación Magnética Transcranel, sus usos en depresión” Charla para el XXIV Congreso Latinoamericano de Psiquiatría, Bávaro, República Dominicana Noviembre 2006.

6.    Mesén A “Es la Esquizofrenia un Trastorno Neurodegenerativo o del Neurodesarrollo? Charla para el simposio “Esquizofrenia Nuevas Aproximaciones, Nuevos Retos” de la Sociedad Venezolana de Psiquiatría, Capítulo Carabobo, Valencia, Venezuela Junio 2007